Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)

  • STATUS
    Recruiting
  • End date
    Apr 15, 2025
  • participants needed
    60
  • sponsor
    Technische Universität Dresden
Updated on 15 September 2021
cytarabine
cell transplantation
induction chemotherapy
mitoxantrone
refractory acute myeloid leukemia (aml)
acute promyelocytic leukemia

Summary

This is an open-label Phase I dose-escalation study of oral venetoclax in combination with increasing cytarabine doses plus mitoxantrone to define the safety profile and MTD of cytarabine in subjects with a histologically or cytologically confirmed acute myeloid leukemia who are refractory or suffered a relapse. This study will be conducted at multiple centers in Germany.

Description

  • To determine safety, tolerability, maximum tolerated dose, and recommended phase II dose of venetoclax in combination with increasing cytarabine doses plus fixed dose mitoxantrone in subjects with a relapsed or refractory AML considered fit for intensive salvage therapy.
    • To assess the preliminary efficacy of venetoclax in combination with increasing cytarabine doses plus fixed dose mitoxantrone in subjects with a relapsed or refractory AML considered fit for intensive salvage therapy.

Details
Condition Relapsed Adult AML
Treatment Venetoclax Oral Tablet
Clinical Study IdentifierNCT04330820
SponsorTechnische Universität Dresden
Last Modified on15 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained before screening
AML according to WHO-2016 criteria, excluding acute promyelocytic leukemia
Relapsed from first or second CR after 1-2 cycles of standard induction chemotherapy (which must have included cytarabine with an anthracycline or anthracenedione), including relapse after allogeneic stem cell transplantation (dose escalation and expansion part)
Age 18-75 years
Fit for intensive chemotherapy, defined by
ECOG 0-2, life expectancy > 3months
Adequate hepatic function: ALAT/ASAT/Bilirubin 2.5 x ULN
unless considered due to leukemic organ involvement Note: Subjects with Gilbert's Syndrome may have a bilirubin > 2.5 ULN per discussion between the investigator and Coordinating investigator
Adequate renal function assessed by serum creatinine 1.5x ULN OR creatinine clearance (by Cockcroft Gault formula) 50 mL/min
Patient is afebrile and hemodynamically stable for at least 72 hours at the time of study medication initiation
Male subjects must agree to refrain from unprotected sex and sperm donation from time point of signing the informed consent until 30 days after the last dose of study drug
Women must fulfill at least one of the following criteria in order to be eligible for trial inclusion
Post-menopausal (12 months of natural amenorrhea or 6 months of amenorrhea with Serum FSH > 40 U/ml)
Postoperative (i.e. 6 weeks) after bilateral ovariectomy with or without hysterectomy
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days before the first dose of study drug
Continuous and correct application of a contraception method with a Pearl Index of <1% (e.g. implants, depots, oral contraceptives, intrauterine device - IUD) from time point of signing the informed consent until 30 days after the last dose of study drug
Note: At present, it is not known whether the effectiveness of hormonal
contraceptives is reduced by venetoclax. For this reason, women should use a
barrier method in addition to hormonal contraceptive methods
Sexual abstinence
Vasectomy of the sexual partner
Inclusion criteria applying for expansion phase (Phase II) only
Primary refractory after 1-2 cycles of standard induction chemotherapy (100 to
mg/m2 cytarabine over 7-10 days plus anthracycline or mitoxantrone over 3
days) or relapsed from first or second CR after 1-2 cycles of standard
induction chemotherapy (which must have included cytarabine with an
anthracycline or anthracenedione), including relapse after allogeneic stem
cell transplantation

Exclusion Criteria

Acute promyelocytic leukemia (AML M3)
CNS involvement or subjects with extramedullary disease only
Known hypersensitivity to excipients of the preparation or any agent given in association with this study including cytarabine or mitoxantrone
Intended hematopoietic stem cell transplantation planned as early conditioning from aplasia without previous blood count recovery
Cumulative previous exposure to anthracyclines of >410 mg/m2 doxorubicin equivalents
Acute GVHD grade 2, extensive chronic GVHD or requiring systemic immunosuppressive therapy within 2 weeks prior to start of study treatment
HIV infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax, as well as anticipated venetoclax mechanism-based lymphopenia that may potentially increase the risk of opportunistic infections)
Inability to swallow oral medications
Any malabsorption condition
Treatment with strong and moderate CYP3A inhibitors (see Appendix 1) during screening
Cardiovascular disability status of New York Heart Association (NYHA) Class 2
Class 2 is defined as cardiac disease in which patients are comfortable at
rest but ordinary physical activity results in fatigue, palpitations, dyspnea
or anginal pain
Chronic respiratory disease that requires continuous oxygen use
White blood cell count > 25 109/L. Note: Hydroxyurea is permitted to meet this criterion
AML relapse treatment with any investigational or commercial drug within 14 days before enrolment. Hydroxyurea is allowed until enrolment to control peripheral WBC counts. Toxic effects of previous investigational drug treatment have to recover to Grade <2\
Substance abuse, medical, psychological, or social conditions that may interfere with the subject's cooperation with the requirements of the trial or evaluation of the study results
Pregnant or breastfeeding women. Breastfeeding has to be discontinued before onset of and during treatment and should be discontinued for at least 3 months after end of treatment
History of active or chronic infectious hepatitis unless serology demonstrates clearance of infection (Occult or prior hepatitis B virus (HBV) infection (defined as negative hepatitis B surface antigen and positive total hepatitis B core antibody) may be included if HBV DNA is undetectable, provided that they are willing to undergo monthly DNA testing. Patients who have protective titers of hepatitis B surface antibody after vaccination or prior but cured hepatitis B are eligible. Patients positive for hepatitis C virus antibody are eligible provided PCR is negative for HCV RNA.)
History of clinically significant liver cirrhosis (e.g., Child-Pugh class B and C)
Live-virus vaccines given within 28 days prior to the initiation of study treatment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note